RxDoctor Payments Data

Brian Bradshaw, MD

Internal Medicine · North Chesterfield, VANPI 1033194774

Payments from drug & device makers

$499in general payments, 2019–2025

Across 31 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$131
  • GSK$115
  • Lilly USA, LLC$49
  • Pfizer$34
  • Sumitomo Pharma America, Inc.$32
  • AstraZeneca$27
  • plus $111 from 7 others

What the payments were for

  • Food & beverage$499100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$499 in reported general payments places this provider in the 65th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$100,304
Medicare patients
480
Services billed
5,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide106$146,144
EliquisApixaban88$111,924
OzempicSemaglutide68$90,121
JardianceEmpagliflozin76$62,045
TrulicityDulaglutide29$46,842
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$45,066
XareltoRivaroxaban37$38,384
Tresiba Flextouch U-200Insulin Degludec11$27,669
OxycontinOxycodone Hcl12$19,073
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$18,368
LinzessLinaclotide21$17,643
Lantus SolostarInsulin Glargine,hum.Rec.Anlog74$13,658
FarxigaDapagliflozin Propanediol11$11,284
SymbicortBudesonide/Formoterol Fumarate12$7,344
Humalog Kwikpen U-100Insulin Lispro14$7,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$49$192,986135 claims
PfizerEliquis$34$111,92488 claims
Novo NordiskOzempic$131$90,12168 claims
Boehringer IngelheimJardiance, Stiolto Respimat$14$80,41393 claims
GSKTrelegy Ellipta$115$45,06632 claims
AstraZenecaFarxiga, Symbicort$27$18,62823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in North Chesterfield

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →